No Data
Analysts Conflicted on These Healthcare Names: HCA Healthcare (HCA), Edwards Lifesciences (EW) and Gilead Sciences (GILD)
Goldman Sachs: The Q1 performance of U.S. pharmaceutical stocks is reassuring, and the Industry sentiment is slightly becoming more positive.
Goldman Sachs stated that amid cautious sentiment from investors towards the USA pharmaceutical sector before the Earnings Reports season, the performance of USA pharmaceutical companies that have reported results so far for the first quarter has not been worse than expected, and in some cases, it has even exceeded expectations.
Gilead Sciences: Strong Market Position and Positive Long-Term Outlook Justify Buy Rating
Express News | Gilead : HSBC Raises Target Price to $93 From $82
No Misses Here: Healthcare Earnings Sweep Past Wall Street Estimates
Wall Street's New Tariff Safe Haven: High-Tax Biotech Stocks -- Heard on the Street
小粉红的papa : It seems that not many people pay attention to biopharmaceutical Stocks, it's quite niche.
Everyone only invests in Technology Stocks.